This article is more than 5 years old. Information may no longer be current.
Vildagliptin recommended for treating prediabetes
Treatment with vildagliptin for 12 weeks produced the same improvements in individuals with impaired glucose tolerance as it did in those with type 2 diabetes.
The beneficial effects of vildagliptin (Galvus, Novartis) on incretin levels and islet function are already known in patients with type 2 diabetes. Now, researchers have reproduced these effects in 179 patients with prediabetes.
Results of the double-blind, randomized, parallel-group study showed that after 12 weeks, vildagliptin reduced postprandial glucose excursions by 32%, increased glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide and decreased glucagon in the prediabetic population. The DPP-IV inhibitor also led to increased beta cell function.
The data revealed no significant weight gain or hypoglycemia associated with vildagliptin. The drug was well-tolerated and there were no significant adverse events. According to the researchers, vildagliptin may be a good candidate in this prediabetic population, but further studies are warranted. – by Katie Kalvaitis
Diabetes Care. 2008;31:30-35.
This paper provides evidence that vildagliptin, a member of the new class of antidiabetic drugs called DPP-IV inhibitors, improves the metabolic profile in subjects with impaired glucose tolerance. The overall response to drug treatment was similar to what has been described in trials of diabetic patients with DPP-IV inhibitors: increased levels of GLP-1, reduced levels of glucagon, and maintenance of insulin levels despite lower blood glucose. The interesting feature here is the improvement of glucose metabolism in a group of subjects who have prediabetes, but who share an increased risk for cardiovascular disease with diabetic patients. Vildagliptin was well-tolerated in the subjects with impaired glucose tolerance as it has been in patients with diabetes. While these results do not support widespread treatment of prediabetes with DPP-IV inhibitors they set the stage for larger and longer trials of these medications to examine potential benefits in this patient group.
– David D’Alessio, MD
Director, Division of Endocrinology, University of Cincinnati